1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Bioteque Corporation

Bioteque Corporation

4107.TWO
Bioteque CorporationTW flagTaipei Exchange
117.00
TWD
- -
- -
8.11BMarket Cap
Bioteque Corporation
4107.TWO
(Taipei Exchange)

Recent

price

117.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.36
9.59
10.76
12.06
13.25
16.24
20.3
20.49
23.28
26.82
28.11
26.34
29.01
28.06
29.91
- -
30.79
Revenue per Share
2.18
1.62
2.13
2.71
3.43
4.07
5.17
4.39
5.84
6.7
7.05
6.22
7.12
6.53
7.62
- -
7.77
Basic EPS, GAAP
1.93
1.36
2.08
1.91
1.13
3.86
3.52
3.94
5.09
6.98
6.68
-1.18
-1.19
8.75
8.72
- -
8.75
Free Cash Flow per Basic Share
1.97
1.78
1.5
1.58
1.78
2.32
2.6
3
3.5
4
4
4
4.5
4.5
4.5
- -
5
Dividend per Share
13.84
12.64
13.41
17.1
15.61
16.49
20.87
22.73
24.5
26.71
29.02
30.09
31.82
33.91
36.4
- -
38.37
Book Value per Share
15.67
15.54
16.31
20.35
22.18
24.47
29.98
30.83
33.39
35.9
38.45
40.45
43.75
46.03
49.65
- -
52.01
Tangible Book Value per Share
79
79
78
79
85
78
69
69
69
69
69
69
69
69
69
- -
69
Basic Weighted Avg Shares
822
760
842
958
1,124
1,259
1,407
1,420
1,613
1,859
1,948
1,825
2,010
1,945
2,073
2,135
2,135
Sales/Revenue/Turnover
21.25
13.92
18.43
24.69
26.55
29.24
31.18
30.15
30.33
31.23
31.16
30.02
28.77
29.83
31.03
31.39
31.39
Operating Margin (%)
56
61
66
68
66
73
78
79
86
96
112
122
132
156
163
172
172
Depreciation Expense
173
129
167
215
291
316
358
304
405
464
489
431
494
453
528
539
539
Net Income, GAAP
12.79
7.77
14.2
13.46
13.53
21.19
18.71
22.68
21.4
21.67
18.8
19.87
20.8
20.54
22.13
20.08
20.08
Effective Tax Rate (%)
21.01
16.91
19.78
22.47
25.89
25.07
25.46
21.4
25.11
24.97
25.09
23.62
24.55
23.27
25.49
25.25
25.25
Profit Margin (%)
759
723
758
1,058
1,088
966
1,070
1,185
1,305
1,451
1,647
1,351
1,344
1,509
1,650
1,786
1,786
Working Capital
205
172
124
154
159
57
40
45
10
11
322
415
824
734
582
439
439
LT Debt
1,243
1,233
1,277
1,616
1,882
1,898
2,077
2,137
2,314
2,488
2,664
2,803
3,032
3,190
3,441
3,607
3,607
Total Equity
10.01
6.56
9.12
12.48
13.05
13.18
15.63
14.13
15.78
17.85
17.21
13.61
12.53
11.35
11.91
12.56
12.56
Return on Invested Capital (%)
12.94
10.23
13.85
15.82
19.05
20.32
22.53
18.03
22.71
25.07
22.7
17.43
17.63
14.61
16.46
16.72
16.72
Return on Capital (%)
15.72
12.25
16.24
17.88
21.69
24.26
26.29
20.12
24.75
26.16
25.31
21.06
23.01
19.87
21.68
20.8
20.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
165
162
158
LT Borrowings
220
187
153
LT Finance Leases
293
290
286
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
8,176
8,288
8,358

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
2,395
2,150
2,333
Cash, Cash Equivalents & STI
1,807
1,517
1,668
Accounts Receivable, Net
184
194
244
Inventories
281
300
294
Total Current Liabilities
887
523
547
Payables & Accruals
- -
- -
- -
ST Debt
165
162
158
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.65%
6.26%
4.83%
Free Cash Flow
-89.86%
-190.8%
0.42%
Net Income, GAAP
6.46%
2.64%
2.07%
Sales/Revenue/Turnover
5.64%
2.04%
3.03%
Total Cash Common Dividend
- -
- -
11.11%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
456
472
498
518
1,945
2024
496
519
553
504
2,073
2025
519
530
519
567
2,135

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1.42
1.48
2.11
- -
6.53
2024
1.81
1.8
2.08
- -
7.62
2025
1.94
1.62
1.97
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.5
2024
- -
- -
- -
- -
4.5
2025
- -
- -
5
- -
- -
Similar Companies
American Medical Technologies Inc. (ADLI)
Supermax Corporation Berhad (7106.KL)
NanoString Technologies, Inc. (NSTGQ)
Sartorius AG (SRT.DE)
Kaisa Health Group Holdings Limited (0876.HK)
Prim, S.A. (PRM.MC)
Business
Bioteque Corporation (4107.TWO) manufactures and markets a broad range of disposable medical devices focused on hemodialysis access, endovascular interventions, respiratory care, and related therapeutic areas; its core products include hemodialysis blood tubing lines, A-V fistula needles, transducer protectors, online HDF sets, closed suction catheters, endotracheal tubes, PTA balloon dilatation catheters, angiographic catheters, sheath introducers, guidewires, pigtail drainage catheter sets, ureteral stents, PCN kits, dialysis catheters, IV infusion bags, precision IV sets, drainage bags, and an extensive array of medical components such as luer locks, drip chambers, filters, clamps, and dialyzer connectors. The company operates manufacturing facilities in Taiwan, including its headquarters facility and the recently completed flagship plant in Yilan Science Park established in 2023 to enhance production capacity and provide comprehensive contract development and manufacturing organization (CDMO) services, as well as a facility in the Philippines; it serves markets across Asia, North America, South America, and other international regions. Founded in 1991 and listed on the Taipei Exchange since 2002, Bioteque Corporation is headquartered at No. 23, Sec. 1, Chang-An East Road, Taipei, Taiwan, and employs over 1,100 people group-wide with facilities accredited to ISO 13485, compliant with FDA, GMP, and EU CE standards. In recent developments, the company completed its new state-of-the-art Yilan Industrial Park facility, boosting capacity for OEM, ODM, OBM, and CDMO orders to capture post-pandemic global demand shifts and support revenue growth, as reflected in its third quarter 2025 earnings release showing EPS of NT$1.97; it continues to pursue product innovations like advanced silicone and TPU catheters while strengthening distributor alliances and sales channels.